Clinical Trial Results:
Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma
Summary
|
|
EudraCT number |
2010-021775-80 |
Trial protocol |
DE |
Global end of trial date |
13 Jan 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Sep 2021
|
First version publication date |
16 Sep 2021
|
Other versions |
|
Summary report(s) |
Final_report_ProGIT_2010-021775-80 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ProGIT
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01466465 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Charité - Universitätsmedizin Berlin
|
||
Sponsor organisation address |
Charitéplatz 1, Berlin, Germany, 10117
|
||
Public contact |
Margitta Worm, Charité - Universitätsmedizin Berlin
Dpt. of Dermatology
Division of Allergy and Immunology, margitta.worm@charite.de
|
||
Scientific contact |
Margitta Worm, Charité - Universitätsmedizin Berlin
Dpt. of Dermatology
Division of Allergy and Immunology, margitta.worm@charite.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Jan 2016
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
13 Jan 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Jan 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to determine whether concomitant vitamin D supplementation promotes that the allergen specific immunotherapy-induced action onset regarding the intracutaneous test reaction to 500 SBU grass pollen.
|
||
Protection of trial subjects |
All clinical tests (blood draw, skin prick test, intracutaneous test, conjunctival provocation tests) and therapeutic interventions (immunotherapy injection) were performed according to defined SOPs and clinical standards.
An patient insurance in accordance with the Medicines Act, Section 40, Paragraph 3) was provided for the probands for travel to the study center and for potential therapeutic side effects.
As no specific e.g. painful procedures were performed, no specific procedures were required.
|
||
Background therapy |
All participants were grass pollen-allergic and all patients were treated with a regular grass pollen-specific immunotherapy according to the manufacturer's instructions. | ||
Evidence for comparator |
Vitamin D receptors control the IgE class switch in B lymphocytes. Activated immune cells can synthesize the active metabolite of vitamin D, calcitriol, from its precursor. In mice, adjacent vitamin D to specific immunotherapy enhance the immunoregulation and beneficial impact on experimental murine allergic airway inflammation. Also in human, vitamin D supplementation can target immune cells, including B lymphocytes. In summary, supplementation of vitamin D to otherwise deficient individuals should enhance the immunomodulatory effect of specific immunotherapy. | ||
Actual start date of recruitment |
18 Oct 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 36
|
||
Worldwide total number of subjects |
36
|
||
EEA total number of subjects |
36
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
36
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Recruitment via the in-house outpatients clinics of grass pollen-allergic individuals with hay fever +/- allergic asthma, who planned a specific immunotherapy | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Grass pollen allergy No sun/UV-exposure planned during the treatment period (November-April) No contraindication against immunotherapy (e.g. uncontroled asthma, planned pregnancy) | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
overall trial (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Assessor | ||||||||||||||||||||||||
Blinding implementation details |
The participants were randomly assigned to the vitamin D or placebo group by the Charité pharmacology Dept. The cholecalciferol or placebo control drug (neutral oil, Migliol® carrier substance of Vigantol®) was packaged identically to maintain the double-blind character. The safety laboratory (serum 25OHD, calci-um, phosphate) were checked by unblinded study personel to exclude a bias by the blinded physician who were in direct contact within direct contact with the study participants
|
||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Vitamin D | ||||||||||||||||||||||||
Arm description |
active drug | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Vigantol Öl
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Oral drops, liquid
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
vitamin D (5,333 I.U./day) was orally applied by 8 drops daily (2013/2014 10 drops due to a new packaging device and drop size).
It was applied daily between visit 1 and 10 in 3 consecutive treatment years (total 3x 4.5 months).
|
||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||
Arm description |
Migliol® (neutral carrier oil) | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
Migliol
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Oral drops, solution
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
The comparator was orally applied by 8 drops daily (2013/2014 10 drops due to a new packaging device and drop size).
It was applied daily between visit 1 and 10 in 3 consecutive treatment years (total 3x 4.5 months).
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Vitamin D Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
all data
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Placebo group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All data
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Vitamin D
|
||
Reporting group description |
active drug | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Migliol® (neutral carrier oil) | ||
Subject analysis set title |
Vitamin D Group
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
all data
|
||
Subject analysis set title |
Placebo group
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All data
|
|
||||||||||||||||
End point title |
Intracutaneous 500 SBU | |||||||||||||||
End point description |
Wheal sizes of the intracutaneous test with 500 SBU grass pollen were compared between the verum and placebo group at V11, V2-11 and V3-11. Analysis of the ITT population shows a weak, but significant reduction of the wheal diameter of the highest allergen-dose (500 SBU) after 1 and 3 treatment years, but not after 2 years or follow up. However, the reduction was independent of vitamin D or placebo intake (p=0.5-0.3). This results from the high variability and thus limited group size. At the end of the study, a trend towards a reduced wheal diameter in the vitamin D group was observed when compared to the placebo group (p=0.085).
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
ICT500 |
|||||||||||||||
Statistical analysis title |
T-Test | |||||||||||||||
Statistical analysis description |
Student's T-Test
|
|||||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority [1] | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||
Confidence interval |
||||||||||||||||
Notes [1] - T-Test |
|
||||||||||||||||
End point title |
Area under the curve of the intracutaneous test | |||||||||||||||
End point description |
The area under the curve (AUC) of the titrated intracutaneous test after the 1st, 2nd and 3rd treatment year. The AUC in this setting is mostly dependent on the wheal diameters of the highest pollen concentrations, which were underlying a significant variation. However, overall the AUC of the grass pollen-intracutaneous reaction is significantly reduced compared to baseline after first year (p=0.003) or third year (p=0.0001), but not to follow-up (p=0.5, not shown), the latter most likely due to a small group size or test allergen-batch variation (left). These data support that higher allergen concentrations are required for mediating a positive test result, as expected. Here, the comparison of the groups show comparable data between vitamin D and placebo at all time points (right).
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
AUC-ICT |
|||||||||||||||
Statistical analysis title |
AUC-ICT | |||||||||||||||
Statistical analysis description |
comparison of the area under the curve of both groups
|
|||||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Area under the curve - conjuncitval provocation test | ||||||||||||
End point description |
The overall AUC of the grass-pollen-specific conjunctival provocation test is increased follow-ing immunotherapy, by trend already after the first treatment year failing statistical significance, and more pronounced after all three treatment years (p=0.0010, after FU p=0.0008, not shown). This effect is expected and reflecting higher allergen concentration thresholds to elicit an allergic reaction. However, intergroup differences were not detectable between the vitamin D or placebo subgroup until FU (0.040, higher in the placebo group).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
3 years
|
||||||||||||
|
|||||||||||||
Attachments |
AUC-CPT |
||||||||||||
Statistical analysis title |
AUC-CPT | ||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Retrospectiv symptom score (RSS) | |||||||||||||||
End point description |
The retrospective symptom score (RSS) significantly improved in the ITT (after 1-3 treatment years p<0.0001) and also both treatment groups (PP) by immunotherapy ranging from p=0.0001-0.0039 (data not shown). Finally, at the follow-up visit both study groups were com-parable. Regarding the increased scores at year 2 and 3, a higher pollen count compared to year 1 must be considered (2012=45 particles per m3 (ppm), 2013=110 ppm, 2014=236 ppm).
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
RSS |
|||||||||||||||
Statistical analysis title |
RSS-stats | |||||||||||||||
Statistical analysis description |
comparison between both study groups
|
|||||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Seasonal global symptoms (SGS) | |||||||||||||||
End point description |
General symptom score of the grass pollen season before treatment (2011) to the treat-ment after (2012, 2013 and follow-up 2014). The data show that immunotherapy reduces the symptoms regarding eyes, nose and the lung, which is significant after 3 treatment (Fig.SGS left). This data is strong, as the maximum and overall pollen counts were in-creasing (by coincidence, 2012=45, 2013=110, 2014=236). However, subgroup analysis re-veal no significant difference between the vitamin D and placebo group (Fig.SGS, right).
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
SGS |
|||||||||||||||
Statistical analysis title |
SGS-stats | |||||||||||||||
Statistical analysis description |
comparison between both study groups
|
|||||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Skin prick test (SPT) | |||||||||||||||
End point description |
The data show that a limited but highly significant reduction of the grass pollen-specific skin prick test reaction by specific immunotherapy in % of control (histamine) but also absolute values (mm of the wheal, data not shown). However, comparison between both groups did not identify specific inter-group differences.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
SPT |
|||||||||||||||
Statistical analysis title |
SPT-stats | |||||||||||||||
Statistical analysis description |
compare both groups
|
|||||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
Symptom-Medication-Score (SMS) | |||||||||||||||
End point description |
Symptom-medication-score (SMS) during grass pollen season 2012, 2013 and 2014. For the pollen season 2012 the data shows a pollen-associated increase of the combined symptom-medication-score (SMS) as self-documented from the participants during summer. The data show comparable data between both groups (blue=vitamin D, red dotted=placebo group, both n= 14 returned data sets).
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
3 years
|
|||||||||||||||
|
||||||||||||||||
Attachments |
SMS-year1 |
|||||||||||||||
Statistical analysis title |
SMS-stats | |||||||||||||||
Statistical analysis description |
comparing both groups
|
|||||||||||||||
Comparison groups |
Placebo group v Vitamin D Group
|
|||||||||||||||
Number of subjects included in analysis |
36
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
non-inferiority | |||||||||||||||
P-value |
< 0.05 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Grass-Ig | ||||||||||||
End point description |
Grass-pollen specific Ig-induction. Before SIT, the data show comparable specific IgE serum concentrations between the groups. Specific IgG4 was low/below the detection thresh-old in all participants. As expected, SIT strongly induces specific IgE, but interestingly in the vitamin D group this process is almost abolished. In summary, analysis of the grass pollen-specific IgE serum concentrations are statistically significant between both groups (p=0.031).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
1 year
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Grass-Ig | ||||||||||||
Statistical analysis description |
to compare vitamin D and placebo group
|
||||||||||||
Comparison groups |
Vitamin D Group v Placebo group
|
||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|||||||||||||
Notes [2] - to compare vitamin D and placebo group |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
3 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
all participants
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
77 adverse events occurred in overall 31 different of 36 randomized participants. Most of these were associated to the flu-season during winter (upper respiratory tract infections, headaches), immunotherapy updosing (local skin reactions). All of the AE’s recovered during the study period. 1 SAE occurred independent of the treatment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
18 Jul 2011 |
issue that Vigantol was off-market in 2010-Summer 2011 |
||
14 Apr 2012 |
introduction of a questionaire to assess the symptom-medication-score during pollen season |
||
11 Jul 2012 |
prolongation for 2 more study years |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
High drop rate over 3 years (vitD n=18->12, plc n=18->11) due to the extension from originally planned 1 year to a 3 year trial. Most of the drop out probands were reporting changes in the occupation or left Berlin, so they could not further attend. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/32750735 |